Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
Plain-language summary
This Phase 3 trial is studying Hypericin and Placebo for people with cutaneous T-cell lymphoma (skin lymphoma). Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 17 US locations across multiple states.
Who can join (key eligibility)
- Age 18 Years or older
- See full trial listing for complete eligibility
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Hypericin (DRUG): HyBryte gel (0.25% hypericin) is applied twice weekly for 18 weeks. Treated lesions are covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light. | Placebo (DRUG): Placebo gel is applied twice weekly for 18 weeks. Treated lesions are covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light.
- Drugs / treatments
- Hypericin, Placebo
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details